Rudolf Arnold

TL;DR: Octreotide LAR demonstrates substantial tumor control and shows a more favorable antiproliferative response than placebo as two-thirds of patients treated with octreotide ARL achieved stable disease at 6 mos, and patients treatment-naïve patients with histologically confirmed locally inoperable or metastasized well-differentiated NETs had a 66% risk reduction of tumor progression.

TL;DR: A highly specific monoclonal antibody directed against the C-terminal part of glucagon-like peptide-1 (GLP-1) was raised to immunohistochemically evaluate the distribution of GLP1 containing cells in the entire gastrointestinal tract including pancreas of rat, pig and man.

TL;DR: It is hypothesize that in contrast to GIP the GLP-1 release from L cells is triggered by nervous reflexes, by putative humoral factor(s) being released from the upper small intestine in addition to nutrient stimuli acting at the luminal surface of the gut.

TL;DR: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours and a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

TL;DR: It is concluded that a threshold rate of gastric emptying of glucose must be exceeded to release GLP-1, whereas GIP release is not controlled by gastric emptied, and that the phase of interdigestive motility existing at the time of glucose ingestion did not affect gastrics emptying or any metabolic parameter.